50 patients included in the NISCI study

NISCI (Nogo-A Inhibition in acute Spinal Cord Injury) is a multicenter, multinational, placebo controlled phase-II study for the safety and preliminary efficacy of intrathecal anti-Nogo-A [NG101] in patients with acute cervical spinal cord injury. The purpose of the NISCI trial is to test if an antibody therapy can improve motor function and quality of life of tetraplegic patients.

Until now 50 patients have been included in the trial. The study has been extended by the Horizon2020 program until 2022.

Find more about the trial and eligibility criteria on our website.

In case of any specific question please contact a participating study center.


Hand function recovery

NISCI study @ German TV
Interview with Prof. N. Weidner, Heidelberg (D)
Video here:,video-142420.html

Unique Wings for Life run 9 May 2021

9 May 2021 a unique Wings for Life run starts worldwide at the same time

A new trial finder online

A new trial finder online - find a spinal cord injury clinical trial that interests you under

Wings for Life World Run cancelled

Given the current public health concerns - it has been unfortunately decided to cancel all Runs planned for 3 May.

More >> here

NISCi project in - Die ZEIT ONLINE

Anti Nogo-A im Rahmen der NISCI Studie.
Eiweiße hemmen, damit Nerven sich erholen.

more >>

NISCI study - Interview with Prof. N. Weidner
NISCI in see NCT03935321
ESCIF congress 2019
Wings for Life run 2019
Raising awareness for spinal cord injury research
more here >>
Wings for life run 2018 >> The lancet Vol 17, July 2018
NISCI research

Martin Schwab has achieved what many researchers dream of their entire lives. Due to his discovery, science now understands why injured nerves within the spinal cord don’t re-grow.

Entire interview >> here